Human adenovirus types 3 and 7 (HAdV-3 and HAdV-7) occur epidemically and contribute greatly to respiratory diseases, but there is no currently available licensed recombinant HAdV-3/HAdV-7 bivalent vaccine. Identification of serotype-specific neutralizing antibody (NAb) epitopes for HAdV-3 and HAdV-7 will be beneficial for development of recombinant HAdV-3/HAdV-7 bivalent vaccines. In this study, four NAb epitopes within hexon hypervariable regions (HVRs) were predicted for HAdV-3 and HAdV-7, respectively, by using bioinformatics. Eight hexon chimeric adenovirus vectors with the alternation of only one predicted neutralizing epitope were constructed. Further in vitro and in vivo neutralization assays indicated that E2 (residing in HVR2) and E3 (residing in HVR5) are NAb epitopes for HAdV-7, and E3 plays a more important role in generating NAb responses. Cross-neutralization assays indicated that all four predicted epitopes, R1 to R4, are NAb epitopes for HAdV-3, and R1 (residing in HVR1) plays the most important role in generating NAb responses. Humoral immune responses elicited by the recombinant rAdH7R1 (containing the R1 epitope) were significantly and durably suppressed by HAdV-3-specific NAbs. Surprisingly, the rAd⌬E3GFP-specific neutralizing epitope responses induced by rAdMHE3 (R3 replaced by E3) and rAdMHE4 (R4 replaced by E4) were weaker than those of rAdMHE1 (R1 replaced by E1) or rAdMHE2 (R2 relaced by E2) in vitro and in vivo. Furthermore, rAdMHE4 replicated more slowly in HEp-2 cells, and the final yield was about 10-fold lower than that of rAd⌬E3GFP. The current findings contribute not only to the development of new adenovirus vaccine candidates, but also to the construction of new gene delivery vectors.
T o date, 51 human adenovirus (HAdV) serotypes have been identified and divided into six groups (A to F) based on their morphological, immunogenic, and genomic information (7) . A novel human adenovirus, HAdV-52, was identified recently, but whether it should be considered a novel "serotype" remains disputed (6, 12) . Most HAdV can cause respiratory disease, gastroenteritis, pneumonia, and keratoconjunctivitis, among other diseases (3, 10, 13) . Of these, the acute respiratory diseases induced by the subspecies B1 adenoviruses HAdV-3 and HAdV-7 have occurred epidemically and have caused outbreaks in Asia, Europe, and North America (2, 11, 15, 21, 26, 31) . However, there is currently no efficient antiviral therapy against adenoviruses and, therefore, it is necessary to develop licensed HAdV-3 and HAdV-7 vaccines to help prevent adenovirus infection outbreaks. A simple combined formulation of HAdV-3 and HAdV-7 monovalent vaccines combined to produce a bivalent vaccine might introduce considerable constraints, such as serotype competition and/or dominance. Therefore, a recombinant vaccine containing HAdV-3 and HAdV-7 neutralizing epitopes that elicits protective immunity simultaneously to HAdV-3 and HAdV-7 is required. However, no neutralizing epitopes have been identified for HAdV-3 and HAdV-7 until now.
All adenovirus particles contain a common structure consisting of the nonenveloped capsid, which is 60 to 90 nm in diameter with icosahedral symmetry. Twelve copies of a trimeric hexon form each of the 20 triangular facets of the icosahedron, and trimeric fibers are inserted into the 12 pentameric penton bases at the 12 vertices. All three major structural proteins, the hexon, fiber, and penton, can generate neutralizing antibodies (NAbs) against adenovirus, but the major protein component of the icosahedral capsid, the hexon, is the major target of serotype-specific NAbs (17, 19, 24) . Alignment of available HAdV hexon protein sequences reveals high homology except within the seven hypervariable regions (HVRs). The highly conserved domains of the hexon protein form the core tertiary structure, a pseudohexagonal shape that allows formation of tightly packed hexon arrays within the facets of the icosahedral capsid, and the seven HVRs are localized on the exterior surface of the virion (20) . It is therefore possible to change amino acids in the HVRs without destroying the core tertiary structure of the hexon protein.
A hexon chimeric adenovirus serotype 5 vector was reported to circumvent preexisting antivector immunity by replacing the seven short HVRs on the surface of the HAdV-5 hexon protein with the corresponding HVRs from HAdV-48 without perturbing its core structure (19) . These data indicated that the seven HVRs contained epitopes recognized by serotype-specific NAbs. Therefore, if serotype-specific NAb epitopes for different adenoviruses can be identified, it would be possible to generate polyvalent vaccines by coexpressing different serotype-specific NAb epitopes in the HVRs of hexon proteins. In this study, we sought to identify the serotype-specific NAb epitopes for HAdV-3 and HAdV-7 by construction of a gene replacement strategy. Our study will contribute to the development of new HAdV-3/HAdV-7 recombinant vaccines and gene delivery vectors.
MATERIALS AND METHODS

Defining the potential NAb epitopes of HAdV-3 and HAdV-7 hexons.
The nonconserved domains of HAdV-3 and HAdV-7 hexon proteins were determined by aligning them with the available human hexon protein sequences using the protein BLAST program (Basic Local Alignment Tool; http://blast.ncbi.nlm.nih.gov/Blast.cgi). The EMBOSS antigenic tool (http://binfo.ym.edu.tw/emboss/Apps/antigenic.html) was used to predict antigenic epitopes of the HAdV-3 and HAdV-7 hexon proteins. The potential template structures for modeling HAdV-3 and HAdV-7 hexon proteins were identified by searching them against information in the Protein Data Bank (PDB) by BLAST-P analysis. The Modeler 9v8 tool was used to model the three-dimensional (3D) structure of HAdV-3 and HAdV-7 hexon proteins (8) . The antigenic epitopes that were predicted to be exposed on the capsid surface and located in nonconserved regions were selected as potential sites for recognition by NAbs.
Construction of the mutagenesis vectors pBRAd-MHE1, pBRAd-MHE2, pBRAd-MHE3, pBRAd-MHE4, pBRAd3H7R1, pBRAd3H7R2, pBRAd3H7R3, and pBRAd3H7R4. The plasmid pBRAd⌬E3GFP encoding a HAdV-3 GZ-01 vector (GenBank accession no. DQ099432) and enhanced green fluorescent protein (GFP) with an E3 region deletion was constructed as previously described (32) . The hexon chimeric adenovirus vector pAd3egf/H7, in which the HAdV-3 hexon gene in the pBRAd⌬E3GFP vector was replaced with the hexon gene from HAdV-7, was constructed as previously described (27) . The mutated hexon genes were cloned into small pBRLR shuttle vectors that facilitated transfer of the mutated hexon genes into full-length viral plasmids pBRAd⌬E3GFP or pAd3egf/H7.
(i) Construction of the shuttle vector pBRLR. The L fragment (from nucleotide [nt] 16748 to nt 18435) was amplified from plasmid pBRAd⌬E3GFP using the primers HexonLU and HexonLD (Table 1) and subsequently digested with EcoRI and ClaI and inserted into the EcoRI/ ClaI-digested pBR322 vector to generate the pBRL vector. Fragment R (from nt 21119 to nt 24526) was amplified from plasmid pBRAd⌬E3GFP using the primers HexonRU and HexonRD (Table 1) before being di- HexonLU  5=-AAAGAATTCTATCCAGCCTGAGGTCAAAGTAAGA-3=  HexonLD  5=-GTCATCGATGGGGTGGCCATCTTGAAAG-3=  HexonRU  5=-AAAGGATCCCATGGATGAGCCCACCCTG-3=  HexonRD  5=-AAGGTCGACTGCATGTTCTGGTTTTCTGAAAG-3=  HexU  5=-CCCATCGATGATGCCCCAATGGGCATAC-3=  HexD  5=-CCGGGATCCACCTCAAAAGTCATGT-3=  MHE1D  5=-GTATGTGGTGGCATTGTCTTCTCCCGTTGTAACTATCCA-3=  MHE1U  5=-GGAGAAGACAATGCCACCACATACACATTTGGCATTGCT-3=  MHE2D  5=GTTGTCTGCGGTAATGTCTTTCCCAATTTCCAAACCTTCTTTAG T3=  MHE2U  5=-GAAATTGGGAAAGACATTACCGCAGACAACAAGCCCATTTATGCCGAT-3=  MHE3D  5=-CGAAAAAGCGTCAGCAGCTTC CCTACCATCGAAAAA-3=  MHE3U 5= A3HVR7r  5=-AGCTGTATCAACATTAGCATCTTTTTCCCATCCATTAGCGTCATCGGTTTTAACTTTAATGCCTTGATATGTTTTCGC-3=  HR1r  5=-TACTGCATTGTCTCGATTCGT-3=  HR2r  5=-GCTTTTCTTCTCCTTCAGT-3=  HR5r  5=-CGCTAAAGCTCCTGCAACAGCATC-3=  HR7r  5=-CCATTAGCGTCATCGGTTTTAAC-3=  HU  5=-GGGTATTCCATATGGCCACCCCATCGATGATGCCCC-3=  HD  5=-CCGCTCGAGTTATTGAGGCTCTGGCTGATATG-3=  AD7SPR1  5=-GGCAGTTGTGCTGGGCATG-3=  AD7SPR2  5=-TTCTCTGGAATTAACATTGAAAGGATAG-3=  AD7SPS  5=-CCACTTAATCATAAATCAGGGCAAAA-3=  AD7SPBH 5= gested with BamHI and SalI and insertion into the BamHI/SalI-digested pBRL vector to generate the pBRLR vector.
(ii) Construction of HAdV-3 hexon mutagenesis vectors pBRAd-MHE1, pBRAd-MHE2, pBRAd-MHE3, and pBRAd-MHE4. HAdV-3 hexon mutagenesis vectors pBRLR-MHE1, pBRLR-MHE2, pBRLR-MHE3, and pBRLR-MHE4 were created to facilitate the transfer of mutated hexon fragments from the mutagenesis vectors into the fulllength plasmid pBRAd⌬E3GFP. The mutated HAdV-3 hexon gene fragment MHE1 (or MHE2, MHE3, or MHE4) was mutated by replacing the region encoding the potential neutralizing epitope R1 (or R2, R3, or R4) of the HAdV-3 hexon gene with the region encoding the potential neutralizing epitope E1 (or E2, E3, or E4) of the HAdV-7 hexon gene. These mutated fragments were produced by overlapping PCR extension mutagenesis. For example, the shuttle vector pBRLR-MHE1 was constructed as follows. The primer pair MHE1U and MHE1D contained the complementary mutated region that encoded the E1 epitope from the HAdV-7 hexon gene. A 2,279-bp segment was amplified from plasmid pBRAd⌬E3GFP by using the primers MHE1U and HexD (Table 1 ). In a separate PCR, a 433-bp segment was amplified from plasmid pBRAd⌬E3GFP using the primers MHE1D and HexU (Table 1) . Subsequently, the two PCR products were purified and annealed as a template in a second round of PCR with the primer pair HexU and HexD, to generate a 2,697-bp PCR product, MHE1. This fragment was digested with ClaI/BamHI and inserted into ClaI/ BamHI-digested pBRLR to construct the pBRLR-MHE1 vector. The vectors pBRLR-MHE2, pBRLR-MHE3, and pBRLR-MHE4 were constructed using the same strategy.
The vectors pBRLR-MHE1, pBRLR-MHE2, pBRLR-MER3, pBRLR-MHE4, were digested with EcoRI and SalI, and the digested fragments (LRMHE1, LRMHE2, LRMHE3, and LRMHE4) containing mutated HAdV-3 hexon genes were purified using a gel extract kit (Qiagen). The plasmid pBRAd⌬E3GFP was digested with PacI and AvrII, and the 35-kb fragment without the wild-type hexon gene was purified and served as the backbone, which was used to transformed BJ5183 cells with the linear fragment MHE1, MHE2, MHE3, or MHE4 to reconstruct the mutant viral genome. The presence of mutations in the viral vectors pBRAd-MHE1, pBRAd-MHE2, pBRAd-MHE3, and pBRAd-MHE4 was verified by sequencing cDNA clones for hexon transcripts.
(iii) Construction of HAdV-7 hexon mutagenesis vectors pBRAd-H7R1, pBRAd-H7R2, pBRAd-H7R3,and pBRAd-H7R4. We used the same strategy to construct the HAdV-7 hexon mutagenesis vectors pBRAd-H7R1, pBRAd-H7R2, pBRAd-H7R3, and pBRAd-H7R4. For example, the mutated fragment H7R1 was produced by overlapping PCR extension mutagenesis with primer pair A3HVR1u/HexD, A3HVR1r/ HexU, and HexU/HexD, using pAd3egf/H7 as DNA templates. Then, the fragment H7R1 was cloned into pBRLR to generate shuttle vector pBRLR-H7R1. Finally, the LR-H7R1 fragment was cloned into the pAd3egf/H7 vector to generate HAdV-7 hexon mutagenesis vector pBRAd-MH7R1 by using recombinant DNA technology. The presence of mutations in the viral vectors pBRAd-H7R1, pBRAd-H7R2, pBRAd-H7R3, and pBRAd-H7R4 was verified by sequencing cDNA clones for hexon transcripts.
Before transfection, 4 ϫ 10 5 HEK-293 cells were added to each well of a 24-well plate (Corning) and grown overnight at 37°C in a 5% CO 2 environment. The chimeric viral genomes were released by using AsiSI (New England BioLabs) from the vector backbones and transfected into HEK-293 using the Sofast transfection kit (Xiamen Sunma Biotechnology, China). After 5 days, the transfected cells were harvested, freezethawed for three cycles, and used to infect HEp-2 cells. The recombinant adenoviruses rAdMHE1, rAdMHE2, rAdMHE3, rAdMHE4, rAdH7R1, rAdH7R2, rAdH7R3, and rAdH7R4 were harvested when a 95 to 100% cytopathic effect (CPE) was observed after several passages.
Animals, virus strains, and cells. Female BALB/c mice were purchased from the Animal Center at Sun Yat-sen University and housed under pathogen-free conditions. HAdV-7 strain GZ08 (GenBank accession no. GQ478341), HAdV-3 strain GZ01, rAd⌬E3GFP, and eight recombinant viruses (rAdMHE1, rAdMHE2, rAdMHE3, rAdMHE4, rAdH7R1, rAdH7R2, rAdH7R3, and rAdH7R4) were cultured in HEp-2 cells or 293 cells. Virus particles were purified by using CsCl gradient centrifugation. After purification, the viruses were quantified by real-time PCR and stored at Ϫ80°C. HEp-2 cells and 293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 100 IU/ml penicillin, 100 mg/ml streptomycin, and 10% newborn calf serum.
RT-PCR. To confirm the generation of chimeric viruses, we performed reverse transcription-PCR (RT-PCR) assays with specific PCR primers for the eight chimeric viruses, 1, 2, 3, and 4 and rAdH7R1, rAdH7R2, rAdH7R3, and rAdH7R4. The common sense primer HU and antisense primer HD were located in the conserved regions of HAdV-3 and HAdV-7 hexon protein sequences, and the antisense primers (IMHE1a, IMHE2a, IMHE3a, IMHE4a, HR1r, HR2r, HR3r, and HR4r) were located in the eight mutant regions (E1, E2, E3, and E4 from HAdV-7 strain GZ08 hexon and R1, R2, R3, and R4 from HAdV-3 strain GZ01) of chimeric hexons. Total RNA was extracted from HEp-2 cells infected with rAd⌬E3GFP, HAdV-7, rAdMHE1, rAdMHE2, rAdMHE3, rAdMHE4, rAdH7R1, rAdH7R2, rAdH7R3, or rAdH7R4 and reverse transcribed to cDNA templates. PCR controls included rAd⌬E3GFP cDNA, HAdV-7 cDNA, and total RNA. A PCR using the primer pair HU and HD was performed to test cDNA quality. A PCR using the primer pair HU and IMHE1a (or IMHE2a, IMHE3a, IMHE4a, HR1r, HR2r, HR3r, or HR4r) was performed to examine the stability of chimeric viruses.
Western blotting. HEp-2 cells were infected with the recombinant viruses rAd⌬E3GFP, rAdMHE1, rAdMHE2, rAdMHE3, or rAdMHE4. At 96 h postinfection, cells were harvested and freeze-thawed three times; then the virus suspensions were mixed with 2ϫ loading buffer (1% sodium dodecyl sulfate [SDS], 10% 2-mercaptoethanol, 0.0025% phenol red, and 10% glycerol in 50 mM Tris-HCl [pH 6.8]) and boiled for 5 min at 100°C. Samples were then separated on 10% SDS-polyacrylamide gels and electrophoretically transferred onto nitrocellulose membranes. The membranes were blocked in blocking buffer (1% [wt/vol] bovine serum albumin [BSA], 5% [wt/vol] skim milk in 10 mM phosphate-buffered saline [PBS]) for 2 h and probed with the monoclonal antibody 5D4, which specifically recognizes hexons from HAdV-3 and HAdV-7, as previously described (18) . The membranes were further incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies. The color reactions were performed with 0.1 M Tris-HCl (pH 6.8) containing 0.5 mg/ml diaminobenzidine (Sigma) and 0.01% H 2 O 2 .
Quantitative PCR. To evaluate the replication characteristics of the recombinant viruses rAdMHE1, rAdMHE2, rAdMHE3, rAdMHE4, and rAd⌬E3GFP, real-time quantitative PCR (Q-PCR) was performed using an adenovirus Q-PCR kit (Huayin Corporation, Guangzhou, China). HEp-2 cells were infected with 1 ϫ 10 8 to 1 ϫ 10 9 genome copies of rAd⌬E3GFP, rAdMHE1, rAdMHE2, rAdMHE3, or rAdMHE4. The infected cells were harvested after 12, 24, 36, 48, 60, and 72 h postinfection, and viral genome copies were determined using adenovirus Q-PCR kits. For in vivo neutralization assays, the rAd⌬E3GFP, rAdMHE1, rAdMHE2, rAdMHE3, rAdMHE4, rAdH7R1, rAdH7R2, rAdH7R3, rAdH7R4, and pAd3egf/H7 genome copy numbers were determined using primers AD3GZ01F, AD3GZ01R, and AD3GZ01FB, and the HAdV-7 genome copy numbers were determined using primers AD7SPR1, AD7SPR2, AD7SPS, and AD7SPBH.
As a standard for the determination of adenovirus genome copies, the rAd⌬E3GFP genome was purified and quantified. Amplification was performed using an Applied Biosystems 7500 real-time PCR system. To assess reproducibility, each assay was performed independently three times in duplicate.
Fluorescence-based microneutralization assay. Except for HAdV-7, all recombinant viruses (rAd⌬E3GFP, pAd3egf/H7, rAdMHE1, rAdMHE2, rAdMHE3, rAdMHE4, rAdH7R1, rAdH7R2, rAdH7R3, and rAdH7R4) used in this study encoded enhanced GFP. Fluorescence readings were made using a microplate spectrophotometer (Thermo Vario-skanFlash) to measure the ability of different sera to neutralize these viruses (28) .
Six-to 8-week-old BALB/c mice received 10 10 genome copies of CsCl gradient-purified rAd⌬E3GFP, pAd3egf/H7, HAdV-7, rAdMHE1, rAdMHE2, rAdMHE3, rAdMHE4, rAdH7R1, rAdH7R2, rAdH7R3,or rAdH7R4 intraperitoneally five times at 2-week intervals (seven animals per virus group). Mice were sacrificed, and antisera were used for in vitro neutralization assays. The sera from naïve BALB/c mice were used as negative controls. Nonspecific protection was observed when the dilution of the serum from naïve mice was lower than 1:64. Therefore, all sera used in the neutralization assays were used at an initial dilution of 1:64.
Each polyclonal serum was inactivated at 56°C for 30 min and then serially diluted in PBS, and 150 l of each dilution was mixed with 150 l rAd⌬E3GFP, Ad3/H7, HAdV-7, rAdMHE1, rAdMHE2, rAdMHE3, rAdMHE4, rAdH7R1, rAdH7R2,rAdH7R3, or rAdH7R4 recombinant viruses (ϳ1 ϫ 10 7 virus particles). The antibody-virus mixtures were incubated at 37°C and 5% CO 2 and then transferred into the HEp-2 cells in triplicate (1 ϫ 10 4 cells per well) in 96-well plates and incubated for 72 h. Enhanced GFP expression in HEp-2 cells was measured using a microplate spectrophotometer (Thermo VarioskanFlash [488-nm excitation, 507-nm emission]) (28) . Background fluorescence was equalized to wells containing cells only, and maximum fluorescence was determined based on wells with cells infected only with virus. Due to edge effects on fluorescence readings, the outer 36 wells of 96-well plates were not used in any assay. Each assay included control wells of HEp-2 cells only, HEp-2 cells infected with virus, and HEp-2 cells infected with virus mixed with sera from naïve mice. The neutralizing ability of the serum was calculated as follows: (fluorescence in cells incubated with the antibody-virus mixture Ϫ background fluorescence)/(maximum fluorescence). The NAbs titers were defined as the serum dilutions that resulted in a 70% reduction of maximum fluorescence (cells infected only with viruses).
To confirm the results of fluorescence-based microneutralization assays, neutralization assays were performed under the same conditions, and genome copies of adenovirus were quantified to measure the inhibition of virus infection by different sera using adenovirus Q-PCR kits. In addition, assays were performed independently, three times in duplicate, to assess reproducibility. Furthermore, for further standardization, neutralization assays were performed with the same virus batch and serum batch by the same operator. The NAb titers were defined as the serum dilution that resulted in a 90% reduction of maximum genome copy number (cells infected only with viruses).
CMN assay. The HAdV-7 virus vector does not encode GFP; therefore, colorimetric microneutralization (CMN) assays were used to examine the neutralization abilities of different sera against HAdV-7, as previously described (5) . In brief, sera were inactivated at 56°C for 30 min, then serially diluted in PBS, and 150 l of each dilution was mixed with 150 l of HAdV-7 virus (100 TCID 50 [50% tissue culture infectious doses]) at 37°C for 1 h in 5% CO 2 . Then, 100 l was transferred into 96-well plates containing HEp-2 cells in triplicate. The assays included control wells of HEp-2 cells only, HEp-2 cells infected with virus, and HEp-2 cells infected with virus that was mixed with sera from naive mice. After incubation for 72 h, the culture medium was removed from the wells. One hundred microliters of a 1:5,000 dilution of Finter's neutral red in PBS was added, and the plates were incubated at 37°C in 5% CO 2 for 1 h. All medium was removed, and the wells were gently washed twice with 150 l PBS. A final solution of acid alcohol (50% ethanol, 1% acetic acid in distilled water) was added (100 l per well). The A 550 of the solubilized dye was read on a microplate spectrophotometer (Thermo Varyskan Flash). The assays were performed three times in duplicate to assess reproducibility. The NAb titers were defined as the serum dilution that protected 90% of cells from HAdV-7 infection. The results of the CMN assay were confirmed using Q-PCR assays as described above.
In vivo neutralization assay. Female BALB/c mice with no previous exposure to rAd⌬E3GFP and HAdV-7 were tested by Q-PCR and enzyme-linked immunosorbent assay (ELISA) with blood from tail veins. A total of 168 mice were divided into two groups: 96 mice in group A and 72 mice in group B (see Fig. 5A, below) . In group A, 72 mice were intraperitoneally vaccinated with 10 10 genome copies of different viruses (HAdV-7, rAd⌬E3GFP, rAdMHE1, rAdMHE2, rAdMHE3, or rAdMHE4) four times at 2-week intervals, with 12 mice per virus group. Forty-eight mice in group B received 10 10 genome copies of rAd⌬E3GFP, rAdMHE3, rAd-MHE4, or HAdV-7, with the same vaccination schedule and with 12 mice per virus group. Twenty-four nonvaccinated mice in each group were used as negative controls. Two weeks after the last vaccination, vaccinated mice in group A were anesthetized with diethyl ether and challenged intranasally with 50 l (about 2 ϫ 10 9 genome copies) of live HAdV-7 virus, and vaccinated mice in group B were anesthetized and challenged intranasally with 50 l (about 2 ϫ 10 9 genome copies) of live rAd⌬E3GFP virus. Twelve nonvaccinated mice in each group were challenged with live HAdV-7 or rAd⌬E3GFP virus and used as negative controls. Twelve naïve mice without virus challenge in each group were used as additional negative controls.
Prior to receiving the virus challenge (day 0), three mice in each subgroup were sacrificed, and the lungs were used to examine the genome copies of challenge virus, HAdV-7 or rAd⌬E3GFP. The remaining mice were sacrificed on days 3, 5, and 7 (three mice per time point) after virus challenge. The lungs from the sacrificed mice were harvested and homogenized in a Tissuemizer (Tekmar) in 600 l of homogenization buffer (10 mM Tris-HCl, 2% SDS, and 1 mM EDTA; pH 8.0). The numbers of HAdV-7 or rAd⌬E3GFP copies in the lung tissues were determined by Q-PCR, as described above.
Adoptive transfer assays. To study the inhibitory effects of HAdV-3-specific NAbs to four rAd3/H7-based hexon chimeric viruses, adoptive transfer studies were performed as previously described (25) . BALB/c mice were preimmunized with 10 10 virus particles of wild-type HAdV-3 GZ01 three times, and then IgG was purified from 2 ml of sera pooled from five immunized mice. The purified antibody was then injected into naive mice via the tail vein. For passive antibody transfer, mice were injected via the tail vein with 40 l HAdV-3-specific antibody (with a neutralizing titer of 1:16,000). On the day following adoptive transfer, the neutralizing antibody titers of the sera from recipient mice were measured in a fluorescence-based microneutralization assay as described above, and then the recipient mice were immunized intramuscularly with 5 ϫ 10 9 virus particles of rAd⌬E3GFP, rAd3/H7, rAdH7R1, rAdH7R2, rAdH7R3, and rAdH7R4 vectors, which encoded EGFP. Control mice received adoptive transfer of IgG purified from PBS-injected mice.
At days 12 and 18 postimmunization, the EGFP-specific antibody titers from immunized mice were measured by ELISA. Ninety-six-well plates were coated overnight with 100 l/well of 1 g/ml recombinant GFP (Millipore) and then blocked for 2 h with blocking buffer (PBS, 2% BSA,0.05% Tween 20). Sera dilutions (100-fold dilution of sera obtained at day 12 postimmunization, 40-fold dilution of sera obtained at day 18 postimmunization) were then added to the wells and incubated for 1 h. The plates were washed three times with PBST (PBS, 0.05% Tween 20) and incubated for 1 h with a 1/10,000 dilution of rabbit anti-mouse IgG plus IgM (HϩL)-peroxidase-conjugated affinity-purified secondary antibodies (Jackson ImmunoResearch). The plates were washed four times, and reactions were developed with tetramethylbenzidine, stopped with 2 M H 2 SO 4 , and analyzed at 450 nm with an ELISA plate reader (Thermo Scientific Multiskan MK3).
RESULTS
Analysis of potential serotype-specific NAb epitopes for
HAdV-3 and HAdV-7. Previous studies indicated that epitopes recognized by serotype-specific NAbs may be exposed on the virion surface and reside within the seven HVRs of hexon proteins (1, 17) . Seven HVRs that reside within HAdV-3 and HAdV-7 hexon proteins were identified by alignment of the available human adenovirus hexon protein sequences (4) . Using sequence alignment data and the known 3D structure of hexon proteins from HAdV-2, HAdV-5, and AdC68 as models, four regions within the HAdV-3 hexon (R1, residues 136 to 151; R2, residues 164 to 187; R3, residues 265 to 284; R4, residues 422 to 437) and four regions within the HAdV-7 hexon (E1, residues 136 to 148; E2, residues 161 to 181; E3, residues 258 to 276; E4, residues 415 to 426) were predicted as potential NAb targets (Fig. 1A) . These potential neutralization sites for HAdV-3 and HAdV-7 were located within the HVR1 (R1 and E1), HVR2 (R2 and E2), HVR5 (R3 and E3), and HVR7 of hexon proteins (R4 and E4) (Fig. 1A) . Conserved amino acids were found between the predicted epitopes of HAdV-3 and the corresponding epitopes of HAdV-7 by sequence alignment (Fig. 1B) .
Four hexon chimeric adenovirus vectors were constructed by replacing the predicted epitopes within the HAdV-3 hexon protein with the corresponding epitopes from the HAdV-7 hexon. To identify the neutralizing epitopes for HAdV-7, four hexon chimeric adenoviruses containing predicted NAb epitopes from HAdV-7 were constructed. A recombinant HAdV-3-based vector, rAd⌬E3GFP expressing GFP, was constructed in a previous study (32) . Four recombinant virus vectors, rAdMHE1 (with the predicted R1 epitope of the HAdV-3 hexon protein replaced with the E1 epitope from the HAdV-7 hexon protein), rAdMHE2 (R2 replaced with E2), rAdMHE3 (R3 replaced with E3), and rAdMHE4 (R4 replaced with E4), were constructed by switching one of the predicted epitopes within the hexon protein of rAd⌬E3GFP with the corresponding epitope from the corresponding HAdV-7 hexon (see Fig. 4A, below) . Transmission electron microscope observation indicated that all four recombinant viruses were rescued and packaged successfully in HEp-2 cells (data not shown).
The stabilities of four chimeric hexon sequences were examined in RT-PCR assays. Total RNA was isolated from HEp-2 cells infected with rAdMHE1, rAdMHE2, rAdMHE3, or rAdMHE4 for 10 serial passages, and no virus genomic DNA contamination was detected in PCR assays ( Fig. 2A, lanes 20 to 25) . Then, cDNA templates were prepared, and all of them were suitable for the RT-PCR assays ( Fig. 2A, lanes 14 to 19) . The cDNA template generated from HAdV-7-infected HEp-2 cells was used as a positive control, and the cDNA template generated from rAd⌬E3GFP-infected HEp-2 cells was used as a negative control. RT-PCR assays indicated that all four hexon chimeric vectors remained stable for at least 10 serial passages in vitro without detectable loss of chimeric hexon sequences ( Fig. 2A, lanes 9 to 12) . No changes to the chimeric hexon sequence were detected by sequencing the cloned PCR fragments. The expression of chimeric hexons was confirmed by Western blotting with the monoclonal antibody 5D4, which recognizes a common epitope of the HAdV-3 and HAdV-7 hexon proteins (Fig. 2B) (18) .
Replication efficiencies of four chimeric viruses and rAd⌬E3GFP. During the rescue and purification processes for recombinant viruses, we observed that under the same conditions, a shorter time was needed for rAdMHE4-infected HEp-2 cells to reach a complete CPE than cells infected with other chimeric viruses or rAd⌬E3GFP virus, but it required 2-fold more rAdMHE4-infected HEp-2 cells to acquire 1 ϫ 10 12 rAdMHE4 virus particles compared to cells infected with other viruses. We concluded that the R4 epitope replaced by E4 from the HAdV-7 hexon protein had an impact on the efficiency of rAdMHE4 replication. Q-PCR assays were performed to gain a quantitative understanding of the replication efficiencies of rAd⌬E3GFP and the four recombinant viruses (Fig. 3) . Approximately 10 8 to 10 9 virus particles were used to infect HEp-2 cells. Two days postinfection, the CPE ratios for rAdMHE4-infected cells and rAdMHE2-infected cells was 100% and 80%, respectively, while the CPE ratios for rAdMHE1-, rAdMHE5-, or rAd⌬E3GFP-infected cells were very low (less than 10%). All infected cells were found to reach CPE 3 days postinfection. In addition, the final yield of rAdMHE4 was 10 times lower than that of rAd⌬E3GFP, while rAdMHE1 and rAdMHE3 replicated as well as the parental virus, rAd⌬E3GFP, in HEp-2 cells. The replication efficiency of rAdMHE2 was the highest before 36 h postinfection, but the final yield was similar to that for rAd⌬E3GFP, rAdMHE1, and rAdMHE3. These results demonstrated that all of the chimeric viruses could encapsidate the recombinant genomes, while the replication efficiency of rAdMHE4 was lower than that of the other three chimeric viruses. Of interest, a lower virus titer was required for rAdMHE4 than other chimeric viruses or rAd⌬E3GFP to cause CPE. This may have been be due to the replaced R4 epitope being very important for HAdV-3 virus replication and infection.
Identification of serotype-specific NAb epitopes for HAdV-7 in vitro. In vitro neutralization assays were performed to detect whether anti-HAdV-7 sera could cross-neutralize four chimeric viruses, and the cross-neutralization responses of antirAd⌬E3GFP sera to four chimeric viruses were analyzed too ( Fig.  4B to E) . The NAb titer was defined as the serum dilution that resulted in a 70% reduction of the maximum fluorescence signal (fluorescence signal occurs only in cells infected with viruses that encode GFP), as assessed in a fluorescence-based microneutralization assay as previously described (23, 28) . Sera from naive mice were used as negative controls, and sera from mice preimmunized with the four chimeric viruses were used as positive controls. With sera from HAdV-7-preimmunized mice in neutralization assays, high rAdMHE2-specific NAb titers (log 2 titer, 6) and rAdMHE3-specific NAb titers (log 2 titer, 8) were detected, but rAdMHE1-and rAdMHE4-specific NAb titers were not observed (Fig. 4B) . These data indicate that E2 and E3, but not E1 and E4, are HAdV-7 NAbs targets. With sera from rAd⌬E3GFP-preimmunized mice in neutralization assays, high NAb titers were observed against all four chimeric viruses, and the rAdMHE4 NAb titer was 2 log 2 to 4 log 2 lower than the NAb titers of the other three chimeric viruses (P Ͻ 0.05, Duncan's multiple range test) (Fig. 4B) .
To confirm the results of the inhibition of virus infection by measuring GFP expression, the microneutralization assays were repeated and the chimeric virus genome copy number was determined by Q-PCR (Fig. 4C) . The NAb titer was defined as the serum dilution that resulted in a 90% reduction of maximum of genome copy number (genome copies in cell infected only with viruses). rAdMHE2-specific (log 2 titer, 6) and rAdMHE3-specific (log 2 titer, 8) NAb titers, but not rAdMHE1-and rAdMHE4-specific NAb titers, induced by HAdV-7 were observed. As expected, high NAb titers against all four chimeric viruses were observed. The rAdMHE4 NAb titer was the lowest (P Ͻ 0.005, Duncan's multiple range test). These results supported those of the fluorescence-based microneutralization assays (Fig. 4B) .
Further microneutralization assays were performed to determine whether rAd⌬E3GFP and HAdV-7 could escape the host neutralization response generated by four chimeric viruses ( Fig. 4D and E) . We found that sera from all four groups of mice preimmunized with chimeric virus inhibited rAd⌬E3GFP infection; however, there were meaningful differences in the NAb titers. rAd⌬E3GFP-specific NAb titers induced by rAdMHE4 were 8 log 2 lower than those induced by rAd⌬E3GFP (P Ͻ 0.005, Duncan's multiple range test). rAd⌬E3GFP-specific NAb titers induced by rAdMHE3 were 4 log 2 lower than those induced by rAd⌬E3GFP (P Ͻ 0.005, Duncan's multiple range test), and rAd⌬E3GFP-specific NAb titers induced by rAdMHE2 were 2 log 2 lower than those induced by rAd⌬E3GFP (P Ͻ 0.05, Duncan's multiple range test). No statistical differences in rAd⌬E3GFP NAbs titers were found between anti-rAdMHE1 sera and anti-rAd⌬E3GFP sera in fluorescence-based microneutralization assays (P Ͻ 0.1, Duncan's multiple range test). In the Q-PCRbased microneutralization assay, no statistical differences in rAd⌬E3GFP Nabs titers were found between anti-rAdMHE1, antirAdMHE2, and anti-rAd⌬E3GFP sera (Fig. 4C) . These data indicate that rAd⌬E3GFP NAbs may be directed partially, but not exclusively, against only one of the four predicted epitopes.
HAdV-7 virus does not encode GFP; therefore, CMN assays were performed to determine whether HAdV-7 virus could escape the host neutralizing response generated by the four chimeric viruses (Fig. 4D and E) . Anti-rAdMHE2 and antirAdMHE3 sera, but not anti-rAdMHE1 or rAdMHE4 sera, protected HEp-2 cells from HAdV-7 infection. HAdV-7-specific NAb titers generated by anti-rAdMHE2 sera were 2 log 2 lower than those of anti-HAdV-7. HAdV-7-specific NAb titers generated by anti-rAdMHE3 sera and anti-HAdV-7 sera showed no significant differences (P Ͻ 0.05, Duncan's multiple range test). The Q-PCR results were in accordance with the results of the CMN assays. These results further confirmed that the predicted epitopes E2 and E3 from the HAdV-7 hexon protein neutralized epitopes for HAdV-7, and E3 played a more important role in generating NAb responses.
Confirmation of neutralizing epitopes for HAdV-7 in vivo. In vivo neutralization assays were performed to investigate whether the chimeric viruses could generate a host neutralizing response against HAdV-7 and HAdV-3 infection (Fig. 5) . The study design is shown in Fig. 5A . The target organ of HAdV-3 and HAdV-7 is the respiratory system; therefore, lung tissue was chosen for the detection of adenovirus infection. Groups of mice were immunized four times with rAdMHE1, rAdMHE2, rAdMHE3, rAdMHE4, rAd⌬E3GFP, or HAdV-7. Two weeks after the last vaccination, the mice in group A were challenged intranasally with live HAdV-7 virus, and the mice in group B were challenged intranasally with live rAd⌬E3GFP virus. Mice were then sacrificed after virus infection on days 0 (before HAdV-7 or rAd⌬E3GFP (B and C) Assessment of rAdMHE1-, rAdMHE2-, rAdMHE3-, and rAdMHE4-specific NAb titers induced by anti-rAd⌬E3GFP or anti-HAdV-7 sera. Sera from mice preimmunized by the hexon chimeric virus itself were used as positive controls, and sera from naïve mice were used as negative controls. (D and E) Assessment of rAd⌬E3GFP and HAdV-7-specific NAb titers induced by anti-rAdMHE1, anti-rAdMHE2, anti-rAdMHE3, or anti-rAdMHE4 sera. Sera from rAd⌬E3GFP-or HAdV-7-preimmunized mice were used as positive/negative controls. The neutralization assays depicted in panels B to E were performed under the same conditions. (B and D) Hexon chimeric virus NAb titers and rAd⌬E3GFP NAb titers were measured in fluorescence-based neutralization assays. HAdV-7 Nab titers in panel D were measured by CMN assay. (C and E) NAb titers were measured in Q-PCR-based neutralization assays. *, P Ͻ 0.05; **, P Ͻ 0.005. challenge), 3, 5, and 7, and the lung tissues were examined for HAdV-7 or rAd⌬E3GFP infection.
In group A, HAdV-7 genome copies could only be detected in the lung tissues from naïve mice or mice preimmunized with the four chimeric viruses or with rAd⌬E3GFP on days 3 and 5, with higher HAdV-7 genome copies present on day 3 than on day 5. No HAdV-7 genome copies could be detected before HAdV-7 challenge (day 0) or after HAdV-7 challenge on day 7 (Fig. 5B) . No HAdV-7 genome copies were detected in the lungs of mice preimmunized with HAdV-7 on day 3. Very low HAdV-7 genome copy numbers (near the detection limit of the Q-PCR) were detected in mice preimmunized with rAdMHE3 on day 3, and no genome copies were detected on day 5; thus, preimmunization with rAdMHE3 contributed to rapid clearance of HAdV-7 in vivo. HAdV-7 genome copies in mice preimmunized with rAdMHE2 were lower than those in mice preimmunized with rAdH1, rAdMHE4, or rAd⌬E3GFP or in naïve mice on day 3 (P Ͻ 0.05, Duncan's multiple range test). Thus, preimmunization with rAdMHE2 also contributed to the clearance of HAdV-7 in BALB/c mice in vivo. In conclusion, rAdMHE2 and rAdMHE3 generate a host neutralizing response against HAdV-7. The E2 and E3 epitopes were NAb epitopes for HAdV-7, and E3 played a more important role in generating NAb responses; these results were in accordance with the results of the neutralization assays in vitro.
Further neutralization assays in vivo were also performed to investigate whether the chimeric viruses could generate a host neutralizing response against rAd⌬E3GFP. We found that preimmunization of mice with rAdMHE1 or rAdMHE2 contributed equally to the clearance of rAd⌬E3GFP in BALB/c mice, while preimmunization of rAdMHE3 or rAdMHE4 contributed little to the clearance of rAd⌬E3GFP in BALB/c mice (data not shown). To confirm these results, we repeated the neutralization assays in vivo again and focused on the neutralizing responses of rAdMHE3 and rAdMHE4. As shown in Fig. 5C , no significant differences in the numbers of rAd⌬E3GFP genome copies were detected between the mice preimmunized with rAdMHE4 versus HAdV-7 on day 3. The number of rAd⌬E3GFP genome copies in mice preimmunized with rAdMHE3 was lower than that of mice preimmunized with rAdMHE4 but higher than that of mice preimmunizied with rAd⌬E3GFP on day 3 (P Ͻ 0.05, Duncan's multiple range test). The rAd⌬E3GFP genome copy numbers in the lungs of mice preimmunized with rAdMHE3 or HAdV-7 decreased to almost the same level as that of mice vaccinated with rAd⌬E3GFP on days 5 and 7, while the rAd⌬E3GFP genome copy numbers remained relatively high in lung tissues of mice vaccinated with rAdMHE4 and in naive mice. These data indicated that replacement of either the R3 or R4 epitope in the rAd⌬E3GFP vector has a great effect on generating the host neutralization response against rAd⌬E3GFP in vivo, and these results were in accordance with the results of neutralization assays in vitro.
Construction of hexon chimeric adenovirus vectors by replacing the predicted epitopes within the HAdV-7 hexon protein with the corresponding epitopes from the HAdV-3 hexon. The rAd⌬E3GFP-specific NAb responses induced by rAdMHE3 and rAdMHE4 were weaker than those against rAdMHE1 and rAd-MHE2. We doubted that these would play a dominant role in generating the host neutralization response against rAd⌬E3GFP. Therefore, four recombinant adenovirus vectors containing HAdV-7 hexon chimeras were constructed (Fig. 6A) . A recombinant HAdV-7 infection generated by preimmunization with rAdMHE1, rAdMHE2, rAdMHE3, or rAdMHE4. (A) Study design. (B) Mice were preimmunized with rAdMHE1, rAdMHE2, rAdMHE3, rAdMHE4, rAd⌬E3GFP, or HAdV-7 and then challenged with HAdV-7. Q-PCR assays were performed to detect genome copy numbers of HAdV-7 in lung tissues. (C) Mice were preimmunized with rAdMHE3, rAdMHE4, rAd⌬E3GFP, or HAdV-7 and then challenged with rAd⌬E3GFP. Q-PCR assays were performed to detect genome copy numbers of rAd⌬E3GFP in lung tissues. Controls included mice preimmunized with rAd⌬E3GFP or HAdV-7 or naïve mice *, P Ͻ 0.05. to cause CPE, but the final virion yield was the lowest. We speculate that exchanging the R4 epitope on the surface of the HAdV-3 hexon disturbs its interaction with other cell components and boosts cell death, and cell death in turn decreases the replication efficiency of rAdMHE4 in later stages. A recent study indicated that adenovirus transport occurs through a direct cytoplasmic dynein-hexon interaction (2) . Exchanging the R4 epitope on the surface of the HAdV-3 hexon may have an adverse effect on the dynein-hexon interaction, resulting in the retention of viruses in the cytoplasm and cell death. However, the role of the hexon in the CPE needs to be further investigated.
We further identified four serotype-specific NAb epitopes (R1 to R4) for HAdV-3 and two serotype-specific NAb epitopes (E2 and E3) for HAdV-7. Yuan et al. previously reported five NAb epitopes which reside in HVR1, HVR2, HVR4, HVR5, and HVR7 of the HAdV-3 hexon based on molecular modeling (30) . Four NAb epitopes (R1 to R4) identified in this study overlap with four of the five NAb epitopes the other authors reported. Considering that HAdV-3 NAbs target partially, but not exclusively, to all four identified NAb epitopes, further studies will be necessary to examine whether the remaining three HVRs contribute to HAdV-3 or HAdV-7 NAb responses.
Cross-neutralization NAb assays between four rAd3/H7-based hexon chimeric vectors (rAdH7R1, rAdH7R2, rAdH7R3, and rAdH7R4) and rAd⌬E3GFP indicated that all four predicted epitopes are NAb epitopes of HAdV-3, while R1 play the most important role in generating NAb responses (Fig. 6) . Further adoptive transfer studies confirmed that R1 was a dominant NAb epitope (Fig. 7) . We were surprised to find that the rAd⌬E3GFP-specific neutralizing epitope responses induced by rAdMHE3 (R3 replaced by E3) and rAdMHE4 (R4 replaced by E4) were weaker than those of rAdMHE1 (R1 replaced by E1) and rAdMHE2 (R2 relaced by E2) in vitro and in vivo (Fig. 4 and 5) . In accordance, E2 and E3 were identified for HAdV-7 serotype-specific NAb epitopes, but HAdV-7-specific NAb neutralizing epitope responses induced by rAdH7R2 (E2 replaced by R2) and rAdH7R3 were weaker than those for rAdH7R1 (E1 replaced by R1) and rAdH7R4 (E4 replaced by R4) (data not shown). Thus, a dominant NAb epitope candidate may be a good candidate for generating NAb responses, but it may not be a good switched candidate to evade preexisting host neutralization responses generated by parental vectors.
In vitro neutralization assays indicated that E2 and E3 are NAb epitopes for HAdV-7, and E3 plays a more important role in generating NAb responses. Results of neutralization assays in vivo were in accordance with these results. HAdV-7 virus loads detected in different groups of mice preimmunized with different viruses were significantly different on day 3. HAdV-7 virus loads in mice preimmunized with rAdMHE2 and rAdMHE3 were obviously lower than those of mice preimmunized with rAdMHE1, rAdMHE2, or rAd⌬E3GFP (P Ͻ 0.05, Duncan's multiple range test). Thus, both E2 and E3 are good candidates for generation of recombinant vaccines against HAdV-7 infection.
In summary, our studies have identified two serotype-specific NAb epitopes for HAdV-7 and four serotype-specific NAb epitopes for HAdV-3. All of them are located in hexon HVRs. These findings will contribute not only to the development of new vaccines, but also to the development of new gene delivery vectors.
